GPRC5D-Related Oral Adverse Events in Multiple Myeloma
A panel of experts on multiple myeloma reviews GPRC5D-related oral toxicities seen in patients receiving treatment.
This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Oral toxicities with talquetamab are nearly universal, with taste changes in 72% of patients, dry mouth in 40%, and dysphagia in 25% arising within the first month but persisting long term. Usmani observes these issues with all talquetamab-treated patients, but they are disproportionately severe in African American patients. Nutrition and supportive measures start early, with schedule modifications offering the best toxicity mitigation after patients respond. Rodriguez notes taste changes in more than 90% of patients, predominantly loss of savoriness although sometimes complete ageusia. Capturing severity is challenged by coarse grading criteria when even grade 1 changes impact quality of life and appetite. The pathophysiologic mechanism, be it taste bud disruption or salivary changes, remains unclear, complicating symptomatic management.
Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
